$18.80
2.94% today
Nasdaq, Sep 04, 10:04 pm CET
ISIN
IL0011407140
Symbol
URGN

UroGen Pharma Ltd. Stock price

$18.80
-1.08 5.43% 1M
+9.20 95.83% 6M
+8.15 76.53% YTD
+4.83 34.57% 1Y
+11.22 148.02% 3Y
-1.90 9.18% 5Y
+4.82 34.48% 10Y
+4.82 34.48% 20Y
Nasdaq, Closing price Thu, Sep 04 2025
-0.57 2.94%
ISIN
IL0011407140
Symbol
URGN
Industry

Key metrics

Basic
Market capitalization
$896.1m
Enterprise Value
$865.4m
Net debt
positive
Cash
$157.0m
Shares outstanding
46.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
9.5 | 7.3
EV/Sales
9.2 | 7.1
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-3.1%
Return on Equity
1,441.3%
ROCE
-76.7%
ROIC
-364.7%
Debt/Equity
-1.4
Financials (TTM | estimate)
Revenue
$94.2m | $122.6m
EBITDA
$-121.5m | $-126.9m
EBIT
$-123.6m | $-118.5m
Net Income
$-155.0m | $-133.2m
Free Cash Flow
$-123.5m
Growth (TTM | estimate)
Revenue
10.9% | 35.6%
EBITDA
-53.5% | -32.8%
EBIT
-55.1% | -22.5%
Net Income
-36.4% | -5.0%
Free Cash Flow
-43.6%
Margin (TTM | estimate)
Gross
88.5%
EBITDA
-128.9% | -103.6%
EBIT
-131.1%
Net
-164.4% | -108.7%
Free Cash Flow
-131.1%
More
EPS
$-3.2
FCF per Share
$-2.7
Short interest
15.1%
Employees
235
Rev per Employee
$380.0k
Show more

Is UroGen Pharma Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

UroGen Pharma Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a UroGen Pharma Ltd. forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a UroGen Pharma Ltd. forecast:

Buy
86%
Hold
14%

Financial data from UroGen Pharma Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
94 94
11% 11%
100%
- Direct Costs 11 11
25% 25%
11%
83 83
9% 9%
89%
- Selling and Administrative Expenses 142 142
37% 37%
151%
- Research and Development Expense 65 65
24% 24%
69%
-121 -121
54% 54%
-129%
- Depreciation and Amortization 2.09 2.09
267% 267%
2%
EBIT (Operating Income) EBIT -124 -124
55% 55%
-131%
Net Profit -155 -155
36% 36%
-164%

In millions USD.

Don't miss a Thing! We will send you all news about UroGen Pharma Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

UroGen Pharma Ltd. Stock News

Neutral
GlobeNewsWire
14 days ago
PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Positive
Seeking Alpha
17 days ago
UroGen Pharma Ltd. recently secured FDA approval for Zusduri, its second commercial product, which is expected to significantly boost future revenues. Analysts remain bullish, with multiple Buy ratings and price targets between $31 and $47, reflecting optimism about the company's growth trajectory. Despite growing sales, UroGen continues to post net losses and will likely require a capital rais...
Neutral
Seeking Alpha
27 days ago
UroGen Pharma Ltd. (NASDAQ:URGN ) Q2 2025 Earnings Conference Call August 7, 2025 10:00 AM ET Company Participants Christopher Degnan - Chief Financial Officer David Lin - Chief Commercial Officer Elizabeth A.
More UroGen Pharma Ltd. News

Company Profile

UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. Its pipeline includes upper tract urothelial carcinoma, low grade non muscle invasive bladder cancer, carcinoma in situ of the bladder, and overactive bladder. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Head office Israel
CEO Elizabeth Barrett
Employees 235
Founded 2004
Website www.urogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today